The Markers That Matter. The Decision That Counts.
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
SkylineDx and leading institutes to present three abstracts on multiple myeloma risk stratification at the 56th ASH annual meeting
Boston (U.S.) - Rotterdam (NL), November 12, 2014. SkylineDx and leading institutes in
Rotterdam, 5 November 2014. We are proud to present a short video introducing SkylineDx’s new molecular prognostic test
Rotterdam, Leiden 28 October 2014. SkylineDx, an innovative company in the field of
Boston (U.S.) – Rotterdam (NL), 14 October 2014. The Ribeirão Preto Medical School (University
Boston (U.S.) – Rotterdam (NL), 1 July 2014. SkylineDx today announced the
Response to Proteasome Inhibitors Can Be Predicted with Gene Expression Profiling Boston (U.S.A.)